CompletedNot Applicable

A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients

South Korea3,267 participantsStarted 2011-05-23

Plain-language summary

The purpose of this study is to evaluate the safety and tolerability of paliperidone palmitate over a 9-week period for participants with schizophrenia in Korea.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants diagnosed with schizophrenia * Participants prescribed with paliperidone palmitate for acute or maintenance treatment Exclusion Criteria: * Participants who received paliperidone palmitate for other than the approved indication

What they're measuring

Number of participants with adverse events up to Week 9

Timeframe: Up to Week 9

Trial details

NCT IDNCT01819818

SponsorJanssen Korea, Ltd., Korea

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-11-29

View on ClinicalTrials.gov More Schizophrenia trials